ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track

Oric Pharmaceuticals, Inc.

2024-Q3 EPS reported -$1.32

Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.
R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).
Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.
Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.
Appointed Keith Lui as SVP of Commercial and Medical Affairs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.